Avalo Therapeutics stock
AVTXNASDAQAvalo Therapeutics, Inc., HealthcareISIN US05338F3064
34Score 34 out of 100, Weak
Price and trend
41 / 100
Price history
−50% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 51% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 58).
The price is 66% below its 52-week high. Largest decline in 11 years: 100% (February 2019 to May 2025).
Chart figures for advanced users
- SMA 50$12.55
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$15.66
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)58
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.63
- The lowest closing price of the last twelve months.
- Resistance$22.87
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Avalo Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $445.24M, is number 245 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $59K (down 86.6% year on year) and a loss of $78.26M.
- MEQIRI Score 34 out of 100 (Weak): rank 644 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $392.97M, financial debt $153K.Stability 69
Weaknesses
- Loss-makingLoss of $88.65M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 91% a year over the last 12 months.Stability 69
- Negative free cash flowFree cash flow −$61.55M over the last 12 months.Fundamentals 17
The score is held back by fundamentals and momentum.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 32 to 34.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
The share count in the financial statements does not match the market value (factor 0.2). Per-share figures such as the P/E and the fair value are therefore treated as not measured until the data match.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 86.6% on the prior year. Revenue has declined since 2024 (-87% per year), so it is worth watching closely. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −123602%, net −132642%. Last 12 months: net −100%. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 22 Mar 2027in 130 days
- Last reported
- 5 Nov 2026EPS reported −$0.34 (expected −$0.59)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$2.91+0.2%
- Revenue
- $1M0.0%
- Earnings per share
- −$2.91+2.4%
- Revenue
- $1M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $2.14M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Sullivan Christopher RyanSale
16 Sept 2026, Chief Financial Officer
- Shares
- 12,394
- Price
- $16.33
- Value
- $202,437
- Sullivan Christopher RyanSale
10 Sept 2026, Chief Financial Officer
- Shares
- 10,185
- Price
- $17.62
- Value
- $179,457
- Doyle MittieSale
28 Aug 2026, Chief Medical Officer
- Shares
- 679
- Price
- $20.00
- Value
- $13,580
Show 10 more
- Sullivan Christopher RyanSale
18 Aug 2026, Chief Financial Officer
- Shares
- 31,031
- Price
- $20.05
- Value
- $622,324
- Sullivan Christopher RyanSale
17 Aug 2026, Chief Financial Officer
- Shares
- 41,694
- Price
- $19.86
- Value
- $828,096
- Doyle MittieSale
17 Aug 2026, Chief Medical Officer
- Shares
- 1,000
- Price
- $20.00
- Value
- $20,000
- Riley JenniferSale
11 Aug 2026, Chief Strategy Officer
- Shares
- 2,655
- Price
- $19.59
- Value
- $52,012
- Doyle MittieSale
10 Aug 2026, Chief Medical Officer
- Shares
- 679
- Price
- $20.00
- Value
- $13,580
- Doyle MittieSale
27 Jul 2026, Chief Medical Officer
- Shares
- 1,000
- Price
- $20.00
- Value
- $20,000
- Doyle MittieSale
30 Jun 2026, Chief Medical Officer
- Shares
- 4,654
- Price
- $20.00
- Value
- $93,080
- Doyle MittieSale
23 Jun 2026, Chief Medical Officer
- Shares
- 1,450
- Price
- $18.00
- Value
- $26,100
- Doyle MittieSale
28 May 2026, Chief Medical Officer
- Shares
- 679
- Price
- $16.00
- Value
- $10,864
- Doyle MittieSale
15 May 2026, Chief Medical Officer
- Shares
- 3,000
- Price
- $18.76
- Value
- $56,280
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Avalo Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 34
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- DiaMedica TherapeuticsDMAC $520.92M46
- Egetis TherapeuticsEGTX.ST $520.6M42
- Shattuck LabsSTTK $514.3M31
- Phathom PharmaceuticalsPHAT $510.51M29
- MiMedx GroupMDXG $484.47M37
- Relmada TherapeuticsRLMD $472.55M38
- Oculis HoldingOCS $469.78M30
- BlossomHill TherapeuticsBLSM $468.79M43
ETFs that hold Avalo Therapeutics
Held by 6 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.00% | 0.45% | €1.53B |
Show 2 more
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.6B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.